Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Weight loss · Compound

Mazdutide

Dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and studied in clinical trials for body-weight reduction.

Philippines Peptides editorial deskUpdated Trial data checked 23 September 20264 min read

Mazdutide is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does.

What is Mazdutide

Mazdutide (IBI362) is a dual GLP-1 receptor and glucagon receptor agonist developed by Innovent Biologics in China. Retatrutide also targets both of these receptors and adds a third, the GIP receptor; mazdutide targets GLP-1 and glucagon receptors only. Browse all weight loss peptide options to compare.

Mazdutide is not in the evidence and trial datasets this site draws on, and this page lists no study sources for it, so the page states no trial figures for mazdutide. For GLP-1 compounds whose trial findings are covered on this site, see tirzepatide and semaglutide.

How it works

Receptor targets: mazdutide is a synthetic peptide designed to activate two receptors, the GLP-1 receptor and the glucagon receptor.

GLP-1 receptor: the receptor that semaglutide and the GLP-1 component of tirzepatide also activate. Its known roles include appetite, insulin secretion and the rate of gastric emptying.

Glucagon receptor: the receptor through which the hormone glucagon acts, mainly in the liver, where it is involved in energy expenditure and fat metabolism. This page cites no study measuring these effects for mazdutide.

Benefits studied

Mazdutide is not yet in the evidence datasets this site draws on, so this page makes no claim about what it does. Anything published about it elsewhere should be read with its evidence level in mind: most peptides in this category have animal or cell data only.

Side effects reported

No controlled human data on adverse events for Mazdutide is in the datasets this site draws on, so its safety in people is unknown rather than established. Effects commonly described for it are listed below; how often they occur has not been measured in a controlled trial.

  • Nausea
  • Decreased appetite
  • Diarrhea
  • Vomiting
  • Injection site reactions
  • Elevated liver enzymes
  • Low blood sugar alongside diabetes medicines
  • Gallbladder problems
  • Pancreatitis

Regulatory status

The regulatory dataset this site draws on has no row for Mazdutide.

Who should not use Mazdutide

FAQ

What is the regulatory status of mazdutide in the Philippines?

The regulatory dataset this site draws on has no row for mazdutide, so this page makes no claim about its registration with FDA Philippines or its approval status elsewhere. Status for the compounds that dataset covers is on the regulatory status page.

How does mazdutide differ from tirzepatide?

The two differ in their second receptor target. Tirzepatide activates the GLP-1 and GIP receptors; mazdutide activates the GLP-1 and glucagon receptors. This page makes no comparison of their trial results because it cites no mazdutide trial source.

What evidence exists for mazdutide?

Mazdutide is not in the evidence datasets this site draws on, and this page lists no study sources for it, so the page states no evidence level or trial figures. The side effects listed on this page are not frequencies measured in a controlled trial.

Where to get Mazdutide in the Philippines

Primara Labs, our partner and supplier, lists their current vials on the catalogue. Prices and stock change, so check there for what is available now. View the Primara Labs catalogue

The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.

View Supply Index

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

Editorial Status
Non-clinical
Affiliation
Not a clinic · Not a pharmacy
Last Updated
September 24, 2026

Related peptides

Updated